Phaseline

Targets › TNFRSF4

TNFRSF4 (Tumor necrosis factor receptor superfamily member 4): drug programs, companies and trials

8 programs from 8 companies in 9 trials: 6 Phase 1, 3 Phase 2; Oncology; next expected readout Nov 2026.

Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity..; FUNCTION: (Microbial infection) Acts as a receptor for human herpesvirus 6B/HHV-6B. (UniProt, P43489)

Open in Phaseline: the race on TNFRSF4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Southern CaliforniaAnti-OX40 Antibody PF-04518600
OX40 (TNFRSF4) agonist antibody
TNFRSF4Phase 2Clear Cell Renal Cell CarcinomaDec 2026
Providence Health & ServicesINBRX-106
OX40 agonist antibody
TNFRSF4Phase 2Triple Negative Breast CancerJun 2027
Inhibrx BiosciencesINBRX-106
OX40 receptor agonist antibody
TNFRSF4Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC); Solid TumorDec 2029
Regeneron PharmaceuticalsREGN7075
OX40 (TNFRSF4) agonist antibody
TNFRSF4Phase 1Advanced Solid TumorsNov 2026
Ruijin HospitalCS01
Agonistic anti-OX40 monoclonal antibody
TNFRSF4Phase 1Locally Advanced or Metastatic Solid TumorsDec 2026
GSKGsk-3174998 (GSK3174998)
Tumor necrosis factor receptor superfamily member 4 agonist
TNFRSF4Phase 1Multiple MyelomaMar 2027
M.D. Anderson Cancer CenterIvuxolimab
OX40 agonist monoclonal antibody
TNFRSF4Phase 1Advanced Malignant Solid NeoplasmApr 2028
Second Affiliated Hospital of Guangzhou Medical UniversityCAR-T cells secreting scFv against OX40
CAR-T cell therapy with engineered OX40 co-stimulation
TNFRSF4Phase 1Lung CancerJun 2029

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC) (1) Solid Tumor (1) Advanced Solid Tumors (1) Multiple Myeloma (1) Locally Advanced or Metastatic Solid Tumors (1) Triple Negative Breast Cancer (1) Clear Cell Renal Cell Carcinoma (1) Advanced Malignant Solid Neoplasm (1) Lung Cancer (1)

Modalities

mixed (5), antibody (2)

Companies

Inhibrx Biosciences (1) Regeneron Pharmaceuticals (1) GSK (1) Ruijin Hospital (1) Providence Health & Services (1) University of Southern California (1) M.D. Anderson Cancer Center (1) Second Affiliated Hospital of Guangzhou Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.